GET DAILY SIGNALSMilestone Pharmaceuticals (MIST): Analyst Targets Point to +813% Upside Potential
Key Takeaways
- The central target of $6.30 represents the arithmetic mean of six verified analyst price targets ranging from $3.00 to $8.00.
- With MIST recently trading near $0.69, reaching $6.30 would imply upside of roughly 813% — a substantial move.
- Analysts lean bullish overall with a Strong Buy bias, though targets vary widely depending on assumptions about how quickly the CARDAMYST launch translates into revenue.
- Positive elements include growing prescriptions, payer coverage now exceeding 50%, and a cash runway extending into the second half of 2027.
- Key risks center on ongoing losses and cash burn, a significant royalty-financing commitment, and uncertainty around reimbursement and the AFib-RVR program.
- Investors can track the company’s Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
Breaking Down the Analyst Price Targets
Milestone Pharmaceuticals Inc. (MIST) develops cardiovascular treatments, with its lead asset CARDAMYST (etripamil) nasal spray receiving FDA approval in December 2025 as the first self-administered option for acute paroxysmal supraventricular tachycardia episodes in adults. I also checked this using Tickeron’s AI Screener to compare the stock against peers in the sector.
Six recent analyst targets span $3.00 to $8.00. H.C. Wainwright and TD Cowen set the high end at $8.00, followed by Wells Fargo and Piper Sandler at $7.00, Raymond James at $5.00 (down from $6.00 in October 2026), and Cantor Fitzgerald at $3.00. The simple average comes to roughly $6.33, which rounds to the $6.30 central target.
The spread highlights differing views. Optimistic analysts point to a much larger opportunity in atrial fibrillation with rapid ventricular response (AFib-RVR), with potential peak CARDAMYST sales of $250 million to $300 million. More cautious voices, such as Raymond James, stress the importance of wider payer coverage, stronger gross-to-net performance, and less dependence on copay assistance. Third-party consensus figures sit between about $5.60 and $6.40 depending on the sample and date, showing how sensitive the average remains to the included targets. No individual estimate serves as a guarantee.
Current Market Position and Path to the Target
MIST recently closed near $0.69, close to the bottom of its 52-week range of roughly $0.63 to $3.06 and well below post-approval peaks. Achieving the $6.30 central target would require an advance of about 813%, a sizable move under any measure.
Success hinges largely on commercial execution. The company remains early in the CARDAMYST launch, with around 600 prescriptions written through April 2026 and steady month-over-month growth. Second-quarter 2026 product revenue reached $0.56 million. At a market capitalization near $100 million and cash runway into the second half of 2027, the current valuation reflects considerable doubt about whether this niche therapy can grow into a sustainable business.
Factors That Could Support a Move Toward the Target
- Launch momentum: Prescriptions, prescriber breadth, and repeat use continue to expand, with early net revenue exceeding some expectations.
- Payer coverage: Inclusion on Express Scripts’ national formulary and coverage above 50% should improve access and realized pricing.
- Pipeline optionality: The Phase 3 ReVeRA-301 trial in AFib-RVR could expand the addressable market, while an EMA decision on PSVT is expected in the first half of 2027.
- Balance sheet: Cash and short-term investments of roughly $170.6 million at mid-2026 provide funding into the second half of 2027.
Risks That Could Keep the Target Out of Reach
- Persistent losses: The company posted a net loss of $28.6 million in Q2 2026 against minimal revenue and expects losses to continue.
- Financing overhang: A $75 million royalty-financing obligation directs a portion of future CARDAMYST sales to a third party.
- Reimbursement risk: Commercial progress still depends on the timing and scope of payer decisions, including Medicare.
- Clinical risk: The AFib-RVR program faces endpoint and execution uncertainty; any setback would weaken the bull case.
Technical Levels and Market Structure
The stock trades near its 52-week low of about $0.63, which serves as important support. Resistance appears near the psychological $1.00 level, while the 52-week high of roughly $3.06 remains a more distant overhead barrier. The longer-term trend stays negative after a decline exceeding 60% over the past year, so the shares would need to stabilize above the lows and reclaim higher resistance before any sustained move toward the target becomes technically plausible.
Time Horizon and Key Items to Watch
Analyst targets typically reflect a roughly 12-month horizon, though individual firms vary. I’m watching quarterly prescription and revenue trends, payer-coverage updates, the rate of cash burn, first patient enrollment in the ReVeRA-301 AFib-RVR trial, and the EMA decision expected in the first half of 2027. The next earnings report, anticipated in November 2026, should offer further clarity on launch progress and spending.
Final Assessment
The $6.30 central target for MIST averages six current analyst estimates spanning $3.00 to $8.00, pointing to roughly 813% upside from levels near $0.69. The bullish scenario rests on a successful CARDAMYST launch and the broader AFib-RVR opportunity, while the bearish view focuses on mounting losses, royalty financing, and reimbursement plus clinical uncertainty. The wide range of targets illustrates meaningful disagreement among analysts on the outcome. Reaching the target remains theoretically possible but would require sustained commercial execution, which is far from assured. Investors should monitor prescription trends, payer coverage, and clinical milestones closely.
Exploring Tickeron’s AI Daily Buy/Sell Signals
In my own research process I have found Tickeron’s AI Daily Buy/Sell Signals useful for adding a systematic layer to manual analysis. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. It helps surface opportunities and track evolving trends without replacing individual judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MIST's Stochastic Oscillator is remaining in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 69 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for MIST turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.724) is normal, around the industry mean (3.037). P/E Ratio (-1.063) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of cardiovascular medicines
Industry Biotechnology
Advertisement